A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study with an Open-Label Extension to
Investigate the Efficacy and Safety of a potential new treatment for Adults with Eosinophilic Esophagitis 

Inclusion criteria for Part A Participants who meet all of the following criteria will be eligible to participate: 

1. Participant is 18 to 75 years of age, at the time of signing the informed consent; 
2. Have a documented diagnosis of EoE prior to or at Screening 
3. Have a history of participant-reported weekly dysphagia in the last 4 weeks prior to Screening (Visit 1)
4. Have a stable food diet in the last 4 weeks prior to Screening 

Subjects who meet ANY of the following exclusion criteria will be excluded from the study:

1.  Have a history or presence of any other disease of the GI tract, such as erosive esophagitis Grade 2 or above, eosinophilic gastritis, duodenitis, eosinophilic colitis, major motility disorder of the esophagus, hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, or a history of esophageal surgery, Barrett’s esophagus, inflammatory bowel disease, Celiac disease, significant hiatal hernia, cancer, or proctitis;  
2.   Have untreated and uncontrolled GERD; Note: Treated GERD is defined as treatment with PPI or histamine type 2 receptor antagonist.
3.   Have a current malignancy or previous history of cancer in remission for less than 5 years prior to Screening (Visit 1) Note: Participants will not be excluded if they had localized carcinoma of the skin that was resected for cure.
4. Have been treated with an immunosuppression agent (e.g., systemic corticosteroids, azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, or Janus-kinase inhibitors) within 3 months or 5 half-lives, whichever is longer, prior to Screening (Visit 1);  
5. Are receiving allergen immunotherapy (SC immunotherapy), unless on a stable dose for at least 6 months prior to Screening (Visit 1)
6. You have failed dupilumab treatment; Note: A participant intolerant to dupilumab treatment when receiving adequate dosing is acceptable 
7. You have previously participated in a study with solrikitug or are currently participating in any interventional study with solrikitug
8. A history of alcohol or substance abuse in the last 12 months